-
The Journal of Otolaryngology Feb 2006To determine the effect of oxymetazoline nasal spray on intraocular pressure and retrobulbar hemodynamics in patients with open-angle glaucoma and to compare the results... (Comparative Study)
Comparative Study
OBJECTIVES
To determine the effect of oxymetazoline nasal spray on intraocular pressure and retrobulbar hemodynamics in patients with open-angle glaucoma and to compare the results with those measured in healthy control participants.
STUDY DESIGN
Controlled, prospective clinical trial.
SETTING
University hospital.
METHODS
Thirty patients with open-angle glaucoma and 30 healthy volunteers as controls were topically self-administered oxymetazoline nasal spray three times a day (one spray in each nostril of 0.05% concentration) for 5 days continuously.
MAIN OUTCOME MEASURES
Intraocular pressure and retrobulbar hemodynamics were measured in glaucomatous and normal eyes at baseline and at the end of oxymetazoline application .
RESULTS
Oxymetazoline nasal spray lowered intraocular pressure significantly in both the glaucoma group (p = .02) and the control group (p = .001) after 5 days of treatment. The systemic parameters in the glaucoma and control groups (systolic blood pressure, p = .14 and p = .17; diastolic blood pressure, p = .18 and p = .49; and pulse rate, p = .06 and p = .50, respectively) did not show statistically significant differences during the study period. Additionally, except with a significant decrease in the resistivity index of the central retinal artery in the glaucoma patients (p = .001), oxymetazoline nasal spray did not result in any significant changes in the retrobulbar hemodynamics in both the glaucoma and control groups.
CONCLUSIONS
This study showed that a 5-day treatment with oxymetazoline nasal spray reduced intraocular pressure in both healthy controls and patients with glaucoma under treatment. In addition, it had no significant adverse effects on the retrobulbar hemodynamics.
Topics: Administration, Topical; Adolescent; Adult; Aged; Audiometry; Blood Flow Velocity; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Nasal Decongestants; Ophthalmic Artery; Orbit; Oxymetazoline; Retinal Artery; Sympathomimetics
PubMed: 16527014
DOI: 10.2310/7070.2005.4102 -
The Journal of Dermatological Treatment Mar 2022Post-inflammatory erythema (PIE) is a common sequalae of acne inflammation, persistent post acne erythema (PAE) is cosmetically unacceptable and sometimes its complete... (Clinical Trial)
Clinical Trial
Successful treatment of the face post acne erythema using a topically applied selective alpha 1-Adrenergic receptor agonist, oxymetazoline 1.5%, a controlled left to right face comparative trial.
BACKGROUND
Post-inflammatory erythema (PIE) is a common sequalae of acne inflammation, persistent post acne erythema (PAE) is cosmetically unacceptable and sometimes its complete clearance could not be achieved. Oxymetazoline (OXZ) is a synthetic, direct-acting, sympathomimetic agonist that is highly selective for the 1α-adrenoceptor. It is a potent vasoconstrictor and well known for its ability to clinically 'get the red out'.
AIM
The aim of this study was to evaluate the efficacy and safety of topical oxymetazoline (OXZ) 1.5% in treatment of post acne erythema (PAE) in a left to right face comparative study.
METHODS
This study was conducted on 40 patients diagnosed with post acne erythema for at least 3 months, the left side of the face was treated with topical OXZ 1.5% in liposomal base and was compared to the right side to which topical lipogel was applied as a control.
RESULTS
According to the investigator's global assessment of photographs and the analysis of erythema with image analysis software, topical OXZ was significantly effective in diminishing PAE when compared to topical placebo lipogel.
CONCLUSION
Topical OXZ is a safe and effective treatment for post-acne erythema.
Topics: Acne Vulgaris; Administration, Topical; Adrenergic alpha-Agonists; Erythema; Face; Humans; Oxymetazoline; Treatment Outcome
PubMed: 32602755
DOI: 10.1080/09546634.2020.1789045 -
Dermatologic Surgery : Official... Jun 2015
Topics: Administration, Cutaneous; Adrenergic alpha-Agonists; Blood Loss, Surgical; Hemostasis, Surgical; Humans; Mohs Surgery; Oxymetazoline
PubMed: 25984903
DOI: 10.1097/DSS.0000000000000362 -
The Annals of Otology, Rhinology, and... Feb 2008We investigated the effects of oxymetazoline hydrochloride on the regulation of healthy human nasal ciliary beat frequency (CBF) and its influence on nasal mucociliary...
OBJECTIVES
We investigated the effects of oxymetazoline hydrochloride on the regulation of healthy human nasal ciliary beat frequency (CBF) and its influence on nasal mucociliary transport time (MTT).
METHODS
Changes in (cultured) human nasal CBF in response to increasing concentrations of oxymetazoline within 20 minutes were quantified by use of high-speed digital microscopy. Moreover, the MTT before and after application of 0.05% oxymetazoline was determined by use of the saccharin test.
RESULTS
Whereas no statistically significant difference was identified when compared to basal CBF at the concentration of 0.025% or 0.05%, both 0.10% and 0.20% oxymetazoline induced a significantly lower CBF at the end of the observation period. The decrement induced by 0.20% oxymetazoline appeared earlier. At concentrations ranging from 0.025% to 0.20%, the inhibitory effect was dependent on the concentration of oxymetazoline. In addition, the use of 0.05% oxymetazoline increased the mean (+/- SD) human nasal MTT from 474 +/- 21 seconds to 572 +/- 41 seconds (n = 29).
CONCLUSIONS
The clinical concentration of oxymetazoline, 0.05%, has no obvious inhibitory effect on human nasal CBF in vitro. The increased MTT caused by 0.05% oxymetazoline in vivo is within the normal range.
Topics: Adrenergic alpha-Agonists; Cells, Cultured; Cilia; Humans; Microscopy; Mucociliary Clearance; Nasal Mucosa; Oxymetazoline; Time Factors
PubMed: 18357837
DOI: 10.1177/000348940811700211 -
Otolaryngology--head and Neck Surgery :... Jul 2012
Topics: Animals; Cerebrospinal Fluid Otorrhea; Female; Middle Ear Ventilation; Otoacoustic Emissions, Spontaneous; Oxymetazoline
PubMed: 22745318
DOI: 10.1177/0194599812447051 -
BMC Research Notes May 2020The study aimed to determine the effect of oxymetazoline nasal spray on the patency of the fistula created after dacryocystorhinostomy, specifically: to compare the... (Randomized Controlled Trial)
Randomized Controlled Trial
OBJECTIVES
The study aimed to determine the effect of oxymetazoline nasal spray on the patency of the fistula created after dacryocystorhinostomy, specifically: to compare the success of fistula formation with oxymetazoline versus placebo, and to compare the incidence of post-operative congestion, pain and bleeding with oxymetazoline versus placebo.
RESULTS
The study was a single-center, randomized controlled, triple-masked study involving the patients of the Plastic-Lacrimal service of a national university hospital. Block randomization was done. Dacryocystorhinostomy was performed by a single-masked surgeon. The intervention group used oxymetazoline. The placebo group used sodium chloride. The data were collected by another masked investigator. The study showed no significant difference in terms of congestion, pain and epistaxis between the two groups at day 2 post-operation. The patency, presence of silicone tube, granuloma formation, and presence of bleeding on both day 2 and day 16 post-operation had no difference between the two groups. This study doesn't support the use of oxymetazoline nasal spray after DCR, since it does not decrease the symptoms of congestion, pain and epistaxis after DCR. Aside from being an additional expense for patients, it also does not affect fistula formation and success rate of the surgery. Trial registration Australian New Zealand Clinical Trial Registry: ACTRN12619001394134, Date registered 10/11/2019, Retrospectively Registered.
Topics: Adult; Aged; Dacryocystorhinostomy; Double-Blind Method; Epistaxis; Female; Fistula; Humans; Male; Middle Aged; Nasal Decongestants; Nasal Sprays; Outcome Assessment, Health Care; Oxymetazoline; Pain, Postoperative; Postoperative Complications; Sodium Chloride
PubMed: 32357900
DOI: 10.1186/s13104-020-05076-4 -
The Annals of Otology, Rhinology, and... Feb 1993The effect of topical oxymetazoline hydrochloride on the blood flow of the nasal and sinus mucosa of the rabbit was measured by laser-Doppler flowmetry. Oxymetazoline,...
The effect of topical oxymetazoline hydrochloride on the blood flow of the nasal and sinus mucosa of the rabbit was measured by laser-Doppler flowmetry. Oxymetazoline, the active component in clinically used nose drops, induced a dose-dependent decrease of the nasal mucosal blood flow. This effect has previously been shown in humans and suggests the presence of alpha 2-adrenoceptors in the nasal mucosa of the rabbit. Doses of oxymetazoline used clinically in humans induced a 50% reduction of blood flow in rabbits. Rhythmic variations in blood flow were seen in 30% of the rabbits after administration of oxymetazoline. Additionally, oxymetazoline induced a dose-dependent decrease of the mucosal blood flow in the maxillary sinus when the drug was applied in the nose. A vasoconstricting effect of oxymetazoline on the arteries penetrating the maxillary sinus ostium is a possible explanation. This can have positive as well as negative consequences on acute sinus infections.
Topics: Administration, Intranasal; Animals; Dose-Response Relationship, Drug; Humans; Laser-Doppler Flowmetry; Male; Maxillary Sinus; Mucous Membrane; Nasal Mucosa; Oxymetazoline; Rabbits; Regional Blood Flow
PubMed: 8427497
DOI: 10.1177/000348949310200209 -
Headache Feb 2020
Topics: Administration, Intranasal; Adrenergic alpha-Agonists; Anesthetics, Local; Drug Combinations; Female; Humans; Middle Aged; Migraine Disorders; Oxymetazoline; Tetracaine
PubMed: 31919839
DOI: 10.1111/head.13739 -
European Journal of Pharmacology Apr 1988The intrathecal (i.t.) injection of 100 nmol of oxymetazoline to male, Sprague-Dawley rats significantly increased tail flick latency and paw pressure threshold for 10 h...
The intrathecal (i.t.) injection of 100 nmol of oxymetazoline to male, Sprague-Dawley rats significantly increased tail flick latency and paw pressure threshold for 10 h as compared to i.t. saline-treated rats. Oxymetazoline-induced antinociception was accompanied by a 2 degree C decrease in rectal temperature and a delayed but mild sedative effect. Intrathecal phentolamine (50 micrograms), injected 8 h after i.t. oxymetazoline, completely reversed the analgesic and hypothermic effects but did not affect sedation. The intravenous injection of oxymetazoline (100 nmol) had no effect in the paw pressure test and virtually no effect in the tail flick test. Co-injection of i.t. morphine and i.t. oxymetazoline in a molar ratio of 1:28 resulted in significant potentiation of their antinociceptive effects as determined by isobolographic analysis. For i.t. morphine alone, the ED50 and 95% confidence interval (95% CI) was 3.8 nmol (2.8-5.6) in the tail flick test and 7.7 nmol (5.4-12.8) in the paw pressure test. In the combination, the ED50 (95% CI) of i.t. morphine was 0.7 nmol (0.6-0.8) in the tail flick test and 1.2 nmol (1.1-1.4) in the paw pressure test, corresponding to an approximate 6-fold increase in potency. The data indicate that: (1) the antinociceptive and hypothermic effects of i.t. oxymetazoline at 8 h are mediated by spinal alpha-adrenoceptors; (2) peripheral sites, and probably supraspinal sites, do not contribute to i.t. oxymetazoline-induced antinociception [corrected]; and (3) oxymetazoline potentiates the analgesic effects of morphine in the spinal cord of the naive rat.
Topics: Analgesics; Animals; Dose-Response Relationship, Drug; Drug Synergism; Imidazoles; Injections, Intravenous; Injections, Spinal; Male; Morphine; Oxymetazoline; Phentolamine; Rats; Receptors, Adrenergic, alpha; Spinal Cord
PubMed: 2838306
DOI: 10.1016/0014-2999(88)90115-x -
Rhinology Dec 2018Nasal congestion, often referred to as stuffy nose or blocked nose is one of the most prevalent and bothersome symptoms of an upper respiratory tract infection.... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Nasal congestion, often referred to as stuffy nose or blocked nose is one of the most prevalent and bothersome symptoms of an upper respiratory tract infection. Oxymetazoline, a widely used intranasal decongestant, offers fast symptom relief, but little is known about the duration of effect.
METHODOLOGY
The results of 2 randomized, double-blind, vehicle-controlled, single-dose, parallel, clinical studies (Study 1, n=67; Study 2, n=61) in which the efficacy of an oxymetazoline (0.05% Oxy) nasal spray in patients with acute coryzal rhinitis was assessed over a 12-hour time-period. Data were collected on both subjective relief of nasal congestion (6-point nasal congestion scale) and objective measures of nasal patency (anterior rhinomanometry) in both studies.
RESULTS
A pooled study analysis showed statistically significant changes from baseline in subjective nasal congestion for 0.05% oxymetazoline and vehicle at each hourly time-point from Hour 1 through Hour 12 (marginally significant at Hour 11). An objective measure of nasal flow was statistically significant at each time-point up to 12 hours. Adverse events on either treatment were infrequent. The number of subjects who achieved an improvement in subjective nasal congestion scores of at least 1.0 was significantly higher in the Oxy group vs. vehicle at all hourly time-points on a 6-point nasal congestion scale.
CONCLUSIONS
This study shows for the first time, that oxymetazoline provides both statistically significant and clinically meaningful relief of nasal congestion and improves nasal airflow for up to 12 hours following a single dose.
Topics: Administration, Intranasal; Administration, Topical; Double-Blind Method; Female; Humans; Male; Nasal Decongestants; Nasal Obstruction; Nasal Sprays; Oxymetazoline; Prospective Studies; Rhinomanometry; Treatment Outcome; Young Adult
PubMed: 29785414
DOI: 10.4193/Rhin17.150